Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Milestone Pharmaceuticals Inc.

Calcium channel antagonist for atrial arrhythmias

This article was originally published in Start Up

Executive Summary

Milestone Pharmaceuticals Inc. is developing a short-acting calcium channel blocker to treat a heart arrhythmia called paroxysmal supraventricular tachycardia. PSVT usually isn’t life-threatening and typically resolves on its own, but it is alarming and often leads patients to the emergency room. Milestone envisions that its drug will be used at home as episodes arise. It has a half-life of just one to four minutes and is delivered intranasally to get to the heart quickly.

You may also be interested in...



Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics

Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.

Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart

Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel